Maria Aguinaga, MD
Undersea and Hyperbaric Medicine · Mission, TXNPI 1023338902
Payments from drug & device makers
Across 620 payments — averaging $28.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$5K
- Bsn Medical Inc$3K
- Urgo Medical North America, LLC$2K
- Hydrofera LLC$2K
- Organogenesis Inc.$1K
- Tactile Systems Technology Inc$697
- plus $4K from 27 others
What the payments were for
- Speaking & faculty fees$3,64121%
- Travel & lodging$5783%
- Food & beverage$13,38476%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 236 | $4,771 |
| Bsn Medical Inc | 1 | $2,734 |
| Urgo Medical North America, LLC | 162 | $2,032 |
| Hydrofera LLC | 35 | $1,724 |
| Organogenesis Inc. | 40 | $1,410 |
| Tactile Systems Technology Inc | 41 | $697 |
| KCI USA, Inc. | 8 | $488 |
| AbbVie(2 entities) | 7 | $406 |
| Melinta Therapeutics, LLC | 6 | $324 |
| Misonix Inc | 13 | $295 |
| Paratek Pharmaceuticals, Inc. | 9 | $294 |
| Kerecis Limited | 3 | $294 |
| Aroa Biosurgery Incorporated | 6 | $272 |
| Reddress USA, Inc. | 3 | $228 |
| Amniox Medical, Inc. | 15 | $179 |
| Sechrist Industries Inc | 1 | $155 |
| Reprise Biomedical, Inc. | 3 | $140 |
| Bioventus LLC | 3 | $136 |
| Lifenet Health | 3 | $134 |
| Pfizer | 1 | $118 |
| Next Science LLC | 6 | $116 |
| Solventum Corporation | 3 | $113 |
| E.r. Squibb & Sons, L.L.C. | 1 | $95 |
| Johnson & Johnson | 1 | $92 |
| Novartis | 1 | $90 |
| Mimedx Group, Inc. | 3 | $69 |
| Bard Peripheral Vascular, Inc. | 1 | $47 |
| Abiomed | 1 | $41 |
| Convatec Inc. | 2 | $28 |
| Medline Industries LP | 2 | $27 |
| Coloplast | 1 | $20 |
| Imbed Biosciences Inc. | 1 | $19 |
| Hartmann USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERSAJET II$689
- Renasys$689
- Grafix$689
- PICO$689
- Oasis$689
- Kerecis Omega3 Marigen$592
- VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP$486
- Kerecis SurgiClose$473
- Apligraf$363
- Affinity$272
- PuraPly$240
- HYDROFERA BLUE$227
- Kerecis Omega3 SurgiClose$148
- PURAPLY WOUND MATRIX$147
- HYDROFERA BLUE READY - BORDER$131
- DALVANCE$127
- SNAP$125
- VAC VERAFLO$125
- PREVENA$125
- NUZYRA$124
How this compares
$17,604 in reported general payments places this provider in the 85th percentile of 59 undersea and hyperbaric medicine providers in Texas.
See all undersea and hyperbaric medicine providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 120 | $93,130 |
| Gentamicin Sulfate | 110 | $6,083 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 36 | $753 |
| Mupirocin | 52 | $528 |
| Nystatin | 20 | $509 |
| SsdSilver Sulfadiazine | 16 | $468 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 42 | $400 |
| Levofloxacin | 134 | $393 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 64 | $376 |
| Silver Sulfadiazine | 11 | $356 |
| Clindamycin Hcl | 38 | $325 |
| Ampicillin Trihydrate | 38 | $313 |
| Doxycycline Hyclate | 23 | $283 |
| Triamcinolone Acetonide | 13 | $91 |
| Tramadol Hcl | 12 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $4,771 | $93,130120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 59 undersea and hyperbaric medicine providers in Texas.
Other undersea and hyperbaric medicine in Mission
- Wade FarrowCollege Station$2.2M
- Marcus GitterleNew Braunfels$234K
- Timothy BumannAbilene$154K
- Heather AguirreSan Antonio$98K
- Ronald ScottFrisco$76K
- Andrew ApplewhiteDallas$46K
- Joseph WolcottLubbock$38K
- Noel OliveiraEdinburg$33K
- Jayesh ShahSan Antonio$17K
- Caroline FifeThe Woodlands$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.